Selective adenosine-receptor agonist for resting perfusion scans now on the market

June 24, 2008

Deerfield, IL - The selective A2A adenosine-receptor agonist regadenoson (Lexiscan) is now commercially available for performing resting stress-myocardial perfusion scans, announced Astellas Pharma US, which is marketing the product for its developer and owner, CV Therapeutics [1]. Lexiscan had been approved by the FDA in April of this year [2].

As reported by heart wire at the time, the pharmacologic stressor's approval was based on two phase 3 studies in which its perfusion scans were comparable in quality to those made using another Astellas product, adenosine injection (Adenoscan). Astellas Pharma US is an affiliate of Astellas Pharma Inc of Tokyo.

Unlike Adenoscan, Lexiscan is administered as a non-weight-adjusted rapid IV bolus; Astellas says that its adenosine-receptor selectivity should give the agent a better side-effect profile.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.